Related Experiment Video
Updated: May 7, 2026
10:45
Double In Utero Electroporation to Target Temporally and Spatially Separated Cell Populations
Published on: June 14, 2020
Prostaglandin E2 enhances long-term repopulation but does not permanently alter inherent stem cell competitiveness
Jonathan Hoggatt1, Khalid S Mohammad, Pratibha Singh
1Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN;
Blood
|September 20, 2013
Summary
Short-term prostaglandin E2 (PGE2) exposure transiently improves hematopoietic stem cell (HSC) homing and engraftment. However, PGE2 treatment does not enhance long-term HSC competitiveness or proliferative potential in serial transplantation models.
Area of Science:
- Hematology
- Stem Cell Biology
- Regenerative Medicine
Background:
- Hematopoietic stem cell (HSC) transplantation is crucial for treating hematologic and metabolic disorders.
- Challenges include insufficient stem cell numbers and poor engraftment efficiency.
- Prostaglandin E2 (PGE2) has shown promise in enhancing HSC function and is in clinical trials.
Purpose of the Study:
- To investigate the long-term effects of prostaglandin E2 (PGE2) on hematopoietic stem cell (HSC) competitiveness.
- To analyze the repopulation kinetics and inherent potential of PGE2-treated HSC grafts through serial transplantations.
- To determine if short-term PGE2 exposure leads to lasting improvements in HSC function.
Main Methods:
- Hematopoietic stem cells (HSCs) were exposed to prostaglandin E2 (PGE2).
- PGE2-treated HSC grafts were subjected to 5 serial transplantations to assess repopulation kinetics.
- A head-to-head secondary transplantation model was used to compare long-term HSC competitiveness.
Main Results:
- Prostaglandin E2 (PGE2) treatment did not result in a sustained increase in HSC competitiveness.
- No evidence of enhanced lineage bias or proliferative potential was observed in the long term.
- PGE2 exposure demonstrated transient improvements in HSC homing and initial engraftment capacity.
Conclusions:
- Short-term prostaglandin E2 (PGE2) exposure provides only transient benefits for hematopoietic stem cell (HSC) engraftment.
- PGE2 does not confer a long-term competitive advantage to HSCs.
- The transient enhancement of HSC homing and engraftment by PGE2 warrants further investigation for clinical applications.
Related Concept Videos
01:14Maintenance of the ES Cell State
The cells of the blastocyst inner cell mass only remain pluripotent for a short time. This state of pluripotency and self-renewal can be maintained in embryonic stem (ES) cell culture by adding specific chemicals or growth factors to ensure the cells can continue dividing and later differentiate into different cell types. In some cases, the cells are grown on a feeder layer of differentiated cells, which provides the growth factors and extracellular matrix components necessary for stem cell...
01:19Clinical Applications of Epidermal Stem Cells
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
01:29Somatic to iPS Cell Reprogramming
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012 for this...
01:27Source And Potency Of Stem Cells
Stem cells are undifferentiated cells with extensive self-renewal properties that help them maintain their population during the fetal and adult stages of life. They can specialize in all cell types of the human body. However, their differential potential may vary and can be classified into five types. Stem cells can be (1) Totipotent, (2) Pluripotent, (3) Multipotent, (4) Oligopotent, and (5) Unipotent. Each stem cell has a specific origin; the fertilized egg or zygote is a totipotent cell and...
01:19Multipotency of Hematopoietic Stem Cells
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
01:21Stem Cell Therapy for Tissue Regeneration
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...